Original research
par
Iacono, Anita et al
Date de publication
2023
Géographie
Canada
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Oui
Évalué par des pairs
Yes
L’objectif
Our aim was to examine uptake, characteristics, treatment patterns and retention of individuals initiating extended-release subcutaneous buprenorphine (BUP-ER), a monthly injectable opioid agonist treatment (OAT).
Constatations/points à retenir
On average, people initiating BUP-ER discontinue within the first 6 months of treatment. While BUP-ER is likely providing an important OAT option, the high occurrence of discontinuation, supplementation with buprenorphine/naloxone, and frequent dose increases suggest inadequacy of current dosing recommendations among a proportion of individuals.
La conception ou méthodologie de recherche
Population-based cohort study (n=2,366)
Mots clés
About PWUD
Substitution/OAT
Outcomes
Transitions in care/treatment
